These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 21059092)

  • 1. The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk.
    Yee MS; Pavitt DV; Dhanjil S; Godsland IF; Richmond W; Johnston DG
    Diabet Med; 2010 Dec; 27(12):1392-400. PubMed ID: 21059092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
    Hedblad B; Zambanini A; Nilsson P; Janzon L; Berglund G
    J Intern Med; 2007 Mar; 261(3):293-305. PubMed ID: 17305652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus.
    Sidhu JS; Kaposzta Z; Markus HS; Kaski JC
    Arterioscler Thromb Vasc Biol; 2004 May; 24(5):930-4. PubMed ID: 15001452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
    Stocker DJ; Taylor AJ; Langley RW; Jezior MR; Vigersky RA
    Am Heart J; 2007 Mar; 153(3):445.e1-6. PubMed ID: 17307426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).
    Lonn EM; Gerstein HC; Sheridan P; Smith S; Diaz R; Mohan V; Bosch J; Yusuf S; Dagenais GR;
    J Am Coll Cardiol; 2009 Jun; 53(22):2028-35. PubMed ID: 19477351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.
    Ratner RE; Cannon CP; Gerstein HC; Nesto RW; Serruys PW; Van Es GA; Kolatkar NS; Kravitz BG; Zalewski A; Fitzgerald PJ;
    Am Heart J; 2008 Dec; 156(6):1074-9. PubMed ID: 19033001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance.
    Varghese A; Yee MS; Chan CF; Crowe LA; Keenan NG; Johnston DG; Pennell DJ
    J Cardiovasc Magn Reson; 2009 Jul; 11(1):24. PubMed ID: 19635160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
    Davidson M; Meyer PM; Haffner S; Feinstein S; D'Agostino R; Kondos GT; Perez A; Chen Z; Mazzone T
    Circulation; 2008 Apr; 117(16):2123-30. PubMed ID: 18413496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients.
    Han SJ; Hur KY; Kim YS; Kang ES; Kim SI; Kim MS; Kwak JY; Kim DJ; Choi SH; Cha BS; Lee HC
    Nephrol Dial Transplant; 2010 Mar; 25(3):976-84. PubMed ID: 19875376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers.
    Abdin AA; Baalash AA; Hamooda HE
    J Diabetes Complications; 2010; 24(3):168-78. PubMed ID: 19328014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
    Mazzone T; Meyer PM; Feinstein SB; Davidson MH; Kondos GT; D'Agostino RB; Perez A; Provost JC; Haffner SM
    JAMA; 2006 Dec; 296(21):2572-81. PubMed ID: 17101640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of ultrasound measurements to assess carotid atherosclerosis development in subjects with and without type 2 diabetes.
    Pollex RL; Spence JD; House AA; Fenster A; Hanley AJ; Zinman B; Harris SB; Hegele RA
    Cardiovasc Ultrasound; 2005 Jun; 3():15. PubMed ID: 15958169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.
    Langenfeld MR; Forst T; Hohberg C; Kann P; Lübben G; Konrad T; Füllert SD; Sachara C; Pfützner A
    Circulation; 2005 May; 111(19):2525-31. PubMed ID: 15883215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
    Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
    Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of comprehensive intensive therapies on the change of intima-media thickness of carotid arteries in type 2 diabetic patients: A report of 4-year follow-up with a literature review.
    Cheng LJ; Xu ZR; Zhang Q; Wang ZD; Wu FW; Yang WX
    Diab Vasc Dis Res; 2016 Jan; 13(1):31-40. PubMed ID: 26499916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment.
    Marfella R; D'Amico M; Esposito K; Baldi A; Di Filippo C; Siniscalchi M; Sasso FC; Portoghese M; Cirillo F; Cacciapuoti F; Carbonara O; Crescenzi B; Baldi F; Ceriello A; Nicoletti GF; D'Andrea F; Verza M; Coppola L; Rossi F; Giugliano D
    Diabetes; 2006 Mar; 55(3):622-32. PubMed ID: 16505224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.